Study on the Effectiveness of Oxybutynin for Children with Overactive Neurogenic Bladder Due to Spina Bifida
- Participants:Children
Rare diseases
Investigational molecules
Locations
Oxybutynin hydrochloride is a medication that belongs to the class of drugs known as anticholinergics or antimuscarinic agents. It was first developed to treat conditions related to bladder overactivity and has been in clinical use for several decades. The drug is also known by several brand names including Ditropan, Ditropan XL, Oxytrol, Gelnique, and others depending on the country and formulation [1].
Oxybutynin works by blocking specific receptors called muscarinic receptors, particularly in the bladder muscle (detrusor). This action:
By affecting these muscarinic receptors, oxybutynin effectively reduces involuntary bladder contractions that can cause symptoms such as urgency, frequency, and urinary incontinence [2].
Oxybutynin hydrochloride is primarily used to treat overactive bladder syndrome, which includes symptoms such as:
Clinical trials have shown that oxybutynin reduces these symptoms in adults with OAB, improving quality of life and reducing the number of incontinence episodes [3].
Oxybutynin is effective in treating neurogenic bladder, a condition where nerve damage affects bladder function. This is common in patients with:
In children with neurogenic bladder due to spina bifida, intravesical oxybutynin (administered directly into the bladder) has shown promising results in improving bladder capacity and reducing intravesical pressure, which can help protect kidney function over time [4].
Oxybutynin may also be prescribed for nocturnal enuresis in children, though it's typically not a first-line treatment. Studies have compared it with other medications like desmopressin (Minirin) for this condition [5].
An off-label use of oxybutynin is for the treatment of hyperhidrosis, or excessive sweating. Clinical trials have demonstrated that oxybutynin can reduce sweating in various areas of the body, including:
Patients with hyperhidrosis often experience significant improvement in their quality of life when treated with oxybutynin [6].
Oxybutynin has shown promise in treating hot flashes in women undergoing endocrine therapy after breast cancer, as well as in women who are not candidates for hormone replacement therapy. This represents another important off-label use of the medication [7].
Oxybutynin hydrochloride is available in several formulations, each with different characteristics:
Dosing of oxybutynin varies based on the formulation, patient age, condition being treated, and individual response. General guidelines include:
Clinical trials have consistently shown that oxybutynin effectively reduces symptoms of overactive bladder. Key findings include:
Studies comparing different formulations have found that extended-release versions maintain efficacy while potentially reducing side effects [10].
In patients with neurogenic bladder, particularly children with spina bifida, oxybutynin has demonstrated:
Intravesical administration may be particularly effective in patients who have inadequate response to oral anticholinergics or experience intolerable side effects [11].
For hyperhidrosis, clinical trials have reported:
Many patients report being "satisfied" or "highly satisfied" with oxybutynin treatment for hyperhidrosis [12].
As with any medication, oxybutynin hydrochloride can cause side effects. These vary in frequency and severity based on the formulation used and individual factors.
The extended-release oral formulations and transdermal/topical formulations generally have fewer systemic side effects, particularly dry mouth, compared to immediate-release oral formulations. This is because they avoid the high peak blood levels associated with immediate-release tablets and may reduce metabolism to the active metabolite (N-desethyloxybutynin) responsible for many side effects [13].
Oxybutynin is one of the few anticholinergic medications approved for use in children with neurogenic bladder. Important considerations include:
Older adults may be more susceptible to certain side effects of oxybutynin, particularly:
Lower starting doses and careful monitoring are recommended. Extended-release formulations or transdermal delivery systems may be preferable in this population to minimize side effects [14].
For patients with spina bifida or other neurological conditions affecting the bladder:
Oxybutynin may interact with other medications, including:
Patients should always inform their healthcare providers about all medications, supplements, and herbal products they are taking [15].
Research continues to explore new applications for oxybutynin:
Recent studies have investigated the combination of oxybutynin with atomoxetine for treating obstructive sleep apnea, showing promising results in reducing apnea-hypopnea index in certain patient subgroups [16].
Oxybutynin is being evaluated for managing bladder pain and urinary urgency after surgical procedures, with some evidence suggesting benefit for reducing stent-related discomfort following urological procedures [17].
Research is exploring combination therapies, such as oxybutynin with alpha-blockers (tamsulosin) for treating lower urinary tract symptoms, which may provide superior symptom relief compared to monotherapy [18].
Each condition opens its own overview and trial list
Recruiting trials first
Tell us about your condition – we search every trial in Europe and connect you with the right site.